Llorens F, Thüne K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, Kovatsi E, Pleschka C, Garcia-Esparcia P, Schmitz M, Ozbay D, Correia S, Correia Â, Milosevic I, Andréoletti O, Fernández-Borges N, Vorberg IM, Glatzel M, Sklaviadis T, Torres JM, Krasemann S, Sánchez-Valle R, Ferrer I, Zerr I. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017 Nov 10;12(1):83. PubMed.
AlzBiomarker Database
Meta-Analysis
- AD vs CTRL : Aβ42 (CSF)
- CTRL vs AD : Aβ42 (CSF)
- VaD vs AD : Aβ42 (CSF)
- AD vs CTRL : YKL-40 (CSF)
- CTRL vs AD : YKL-40 (CSF)
- VaD vs AD : YKL-40 (CSF)
- gCJD vs AD : YKL-40 (CSF)
- sCJD vs AD : YKL-40 (CSF)
- AD vs CTRL : tau-total (CSF)
- CTRL vs AD : tau-total (CSF)
- FFI vs AD : tau-total (CSF)
- VaD vs AD : tau-total (CSF)
- gCJD vs AD : tau-total (CSF)
- sCJD vs AD : tau-total (CSF)
Curated Study Data
Biomarker (Source) |
Cohort (N) |
Measurement Mean ± SD |
Method; Assay Name; Manufacturer |
Diagnostic Criteria |
---|---|---|---|---|
Aβ42 (CSF) |
AD (84) |
366 ± 302 pg/mL |
ELISA; Innotest AMYLOID (1–42); Fujirebio |
1991 |
Aβ42 (CSF) |
CTRL- Other Controls (62) |
884 ± 321 pg/mL |
ELISA; Innotest AMYLOID (1–42); Fujirebio |
|
Aβ42 (CSF) |
VaD (20) |
543 ± 203 pg/mL |
ELISA; Innotest AMYLOID (1–42); Fujirebio |
Román et al., 1993; 1991 |
YKL-40 (CSF) |
AD (28) |
311 ± 113 pg/mL |
ELISA; MicroVue YKL-40 EIA; Quidel Corporation |
McKhann et al., 1984 |
YKL-40 (CSF) |
AD (84) |
386 ± 221 pg/mL |
ELISA; MicroVue YKL-40 EIA; Quidel Corporation |
1991 |
YKL-40 (CSF) |
CTRL- Other Controls (62) |
250 ± 77 pg/mL |
ELISA; MicroVue YKL-40 EIA; Quidel Corporation |
|
YKL-40 (CSF) |
CTRL (35) |
226 ± 82 pg/mL |
ELISA; MicroVue YKL-40 EIA; Quidel Corporation |
|
YKL-40 (CSF) |
VaD (20) |
323 ± 96 pg/mL |
ELISA; MicroVue YKL-40 EIA; Quidel Corporation |
Román et al., 1993; 1991 |
YKL-40 (CSF) |
gCJD- E200K (11) |
471 ± 135 pg/mL |
ELISA; MicroVue YKL-40 EIA; Quidel Corporation |
Zerr et al., 2009 |
YKL-40 (CSF) |
gCJD- E200K (11) |
447 ± 161 pg/mL |
ELISA; MicroVue YKL-40 EIA; Quidel Corporation |
Zerr et al., 2009 |
YKL-40 (CSF) |
sCJD (35) |
411 ± 157 pg/mL |
ELISA; MicroVue YKL-40 EIA; Quidel Corporation |
Zerr et al., 2009 |
YKL-40 (CSF) |
sCJD (82) |
480 ± 178 pg/mL |
ELISA; MicroVue YKL-40 EIA; Quidel Corporation |
Zerr et al., 2009 |
tau-total (CSF) |
AD (28) |
757 ± 505 pg/mL |
ELISA; Innotest hTAU Ag; Fujirebio |
McKhann et al., 1984 |
tau-total (CSF) |
AD (84) |
511 ± 429 pg/mL |
ELISA; Innotest hTAU Ag; Fujirebio |
1991 |
tau-total (CSF) |
CTRL- CNC (35) |
221 ± 121 pg/mL |
ELISA; Innotest hTAU Ag; Fujirebio |
|
tau-total (CSF) |
CTRL- Other Controls (62) |
259 ± 124 pg/mL |
ELISA; Innotest hTAU Ag; Fujirebio |
|
tau-total (CSF) |
FFI (11) |
425 ± 411 pg/mL |
ELISA; Innotest hTAU Ag; Fujirebio |
Zerr et al., 2009 |
tau-total (CSF) |
VaD (20) |
435 ± 309 pg/mL |
ELISA; Innotest hTAU Ag; Fujirebio |
Román et al., 1993; 1991 |
tau-total (CSF) |
gCJD- E200K (11) |
4323 ± 4069 pg/mL |
ELISA; Innotest hTAU Ag; Fujirebio |
Zerr et al., 2009 |
tau-total (CSF) |
gCJD- E200K (11) |
2452 ± 1777 pg/mL |
ELISA; Innotest hTAU Ag; Fujirebio |
Zerr et al., 2009 |
tau-total (CSF) |
sCJD (35) |
3688 ± 3532 pg/mL |
ELISA; Innotest hTAU Ag; Fujirebio |
Zerr et al., 2009 |
tau-total (CSF) |
sCJD (82) |
9622 ± 8468 pg/mL |
ELISA; Innotest hTAU Ag; Fujirebio |
Zerr et al., 2009 |
Recommends
Please login to recommend the paper.
This paper appears in the following:
AlzBiomarker
- AD vs CTRL : Aβ42 (CSF)
- CTRL vs AD : Aβ42 (CSF)
- VaD vs AD : Aβ42 (CSF)
- AD vs CTRL : YKL-40 (CSF)
- CTRL vs AD : YKL-40 (CSF)
- VaD vs AD : YKL-40 (CSF)
- gCJD vs AD : YKL-40 (CSF)
- sCJD vs AD : YKL-40 (CSF)
- AD vs CTRL : tau-total (CSF)
- CTRL vs AD : tau-total (CSF)
- FFI vs AD : tau-total (CSF)
- VaD vs AD : tau-total (CSF)
- gCJD vs AD : tau-total (CSF)
- sCJD vs AD : tau-total (CSF)
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.